Navigation Links
Natera Selected for NHS-Funded TRACERx Study of Lung Cancer Heterogeneity Using Cell-Free Tumor DNA
Date:7/8/2015

SAN CARLOS, Calif., July 8, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a research collaboration with University College London (UCL) Cancer Institute, where the Institute will use Natera's proprietary technology to detect variations in cell-free circulating tumor DNA (ctDNA) in the TRACERx study (Tracking Cancer Evolution through Therapy). The study aims to understand how lung cancers mutate, adapt and become resistant to treatments.

TRACERx is a study of 840 patients with non-small cell lung cancer, funded mainly by Cancer Research UK, with additional funding from the Rosetrees Foundation and UCL. It aims to define the evolutionary paths of cancer by sampling and analyzing each tumor several times, both before and after surgery. Tumor sampling will include multiple biopsies of the tumor tissue, as well as liquid biopsy of ctDNA in blood, to measure tumor heterogeneity and its evolution over time.

Natera was selected for the study by the TRACERx investigators at UCL Cancer Institute and Leicester, because of its comparative performance to other technologies in preliminary studies. "Natera's technology will provide a unique view into the clonal and subclonal tumor variations that we wish to track for this study," said Professor Charles Swanton, M.D., Ph.D. and Professor Jacqui Shaw, lead researchers for the TRACERx study.

Natera's novel technology platform, called massively-multiplexed PCR (mmPCR), when combined with its proprietary statistical algorithms, allows for highly sensitive interrogation of point mutations and copy number variations (CNV) from cell-free DNA in blood. The mmPCR technology has been studied and proven in the context of non-invasive prenatal testing (NIPT) for Down syndrome and other common aneuploidies, where Natera is a worldwide leader.

"We are honored to be working with Professor Charles Swanton and Professor Jacqui Shaw in Leicester and University College of London, which have a track record of lung cancer studies in the U.K.," said Matthew Rabinowitz, Ph.D., CEO of Natera. "This collaboration fits perfectly with Natera's mission to transform how people diagnose and manage genetic disease, including lung cancer, which kills more people every year than any other form of cancer. We are pleased that Natera's technology was selected for this landmark study, and we believe it will provide a springboard for Natera's plans to develop and launch commercially available cfDNA-based diagnostics for cancer of the lung, breast and ovaries."

The TRACERx study is expected to enable Natera to demonstrate how its technology can be used to improve cancer patient care and treatment outcomes. Specifically, Natera seeks to learn how ctDNA monitoring recapitulates subclonal evolution in NSCLC (non-small cell lung cancer), how it relates to treatment response, and if it can identify recurrence sooner for more effective treatment.

The study, entitled "Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study," is listed online at ClinicalTrials.gov [NCT01888601].

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Forward-looking statements

This release contains forward-looking statements, including statements regarding the TRACERx Study and Natera's plans to develop and launch commercially available diagnostics and monitoring technology for cancer. Any forward-looking statements contained in this press release are based upon Natera's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including uncertainty in the development and commercialization of our planned future cancer products or other new products or if the results of our clinical studies do not support the use of our tests, or cannot be replicated in later studies required for regulatory approvals or clearances. Additional risks and uncertainties that could affect Natera's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's final prospectus dated July 1, 2015. This is available on the company's website at www.natera.com under the Investors section and on the SEC's website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time.

Contacts
GOLD PR for Natera
Jill Edgeworth, 847-778-1538       
jedgeworth@goldpr.com

Natera, Inc.
Michael Hromadik, 858-442-2215
mhromadik@natera.com

Logo - http://photos.prnewswire.com/prnh/20150403/196532LOGO

 


'/>"/>
SOURCE Natera, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Liquidity Services, Inc. Selected by Hoffmann-La Roche Inc. as Sales Channel for Surplus Assets
2. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
3. Mirixa Selected by The Assist Group
4. Trottas West Street Pharmacy Selected For "Best Of Westchester"
5. SAM Medical Products Selected a Winner in the 34th Annual Telly Awards
6. Liaison Healthcare Selected by Vivature EHR for Lab Orders and Results Integration
7. PRN Physician Recommended Nutriceuticals Selected for the Second Consecutive Year to the Inc. 500
8. 5000 List of Fastest-Growing Privately Held Companies
9. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
10. Novation Big Data Selected by Computerworld as 2013 Data+ Editors Choice
11. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... June 19, 2019 , ... One is never too old to make dreams ... Home (LAJH). Known as a destination for Los Angeles-area seniors, LAJH has an environment ... and Mildred Moccio, it is also a point of embarkation: a place from which ...
(Date:6/19/2019)... ... June 19, 2019 , ... A new survey by The ... $376 per month on healthcare costs. If that doesn’t sound like enough of ... per month, one-in-five survey participants reported spending $1,000 per month or more. The ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... emergency medicine and hospital medicine management services, are pleased to announce the acquisition ... in Longview, Texas. , LEMA’s 34 physicians and 9 advanced practice clinicians ...
Breaking Medicine Technology:
(Date:6/24/2019)... ... 2019 , ... Cibo Vita, Inc., makers of Nature’s Garden, NutriPops, Chocolate Orchard ... indulgence snack line at the 65th annual Summer Fancy Food Show, taking place at ... booth #5721. , The company’s expansive product portfolio features a variety of trail ...
(Date:6/20/2019)... ... , ... Access Healthcare, one of the largest providers of ... appointed as Senior Vice President of Client Services. Angel brings more than 20 ... high performing teams, and driving revenue growth for healthcare companies. , In this ...
(Date:6/19/2019)... (PRWEB) , ... June 19, ... ... from non-governmental organizations, academia, faith-based organizations, private institutions, media, and government joined ... DC to make commitments to improve universal access to water, sanitation, and ...
(Date:6/19/2019)... , ... June 19, 2019 , ... A legal-medical ... the United States, has filed class action lawsuits in 34 of the 48 ... in the class actions are an array of pharmaceutical manufacturers, distributors and retailers, all ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited ... Reproduction and Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s ... consideration for both the Basic Science Award for Oral Presentation and the Fertility Society ...
Breaking Medicine News(10 mins):